|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
DRD2 expression may be regulated by <i>DRD2</i> rs1800497 genotype in patients with migraine.
|
29695928 |
2018 |
|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Nevertheless, decreased risk of migraine was observed to be in association with COMT rs4680 polymorphism in overall analysis (AA vs. GG + GA: OR = 0.76, 95% CI = 0.60-0.97, PHet > 0.642, I = 0), and in Caucasian group after subgroup analysis (AA vs. GG + GA: OR = 0.75, 95% CI = 0.58-0.96, PHet > 0.433, I = 0).Studied polymorphisms of DRD2, DBH, and MAO-A genes may not be associated with migraine susceptibility.
|
26632697 |
2015 |
|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Therefore, we aimed to look for association of functional variants in ANKK1 (rs1800497), DRD2 (rs6275 and rs1799732) and DBH (rs7239728 and rs1611115) genes with migraine susceptibility.
|
22875483 |
2013 |
|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
By multivariate logistic stepwise regression analysis, type of migraine, regular and sufficient dietary intake, and methylenetetrahydrofolate reductase (MTHFR) C677T (rs1801133) and dopamine D2 receptor (DRD2) rs6275" genes_norm="1813">C939T (rs6275) polymorphisms were selected as significant factors that contribute independently to the development from migraine to MOH (P < 0.05).
|
22290307 |
2013 |
|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The multivariate stepwise logistic regression analysis revealed that age, periorbital/deep orbital pain and C/C genotype carrier at DRD2 C939T were significant factors that contributed independently to the negative response to triptans in patients with migraine.
|
21822697 |
2012 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of dopaminergic gene polymorphisms (DBH 19 bp indel and DRD2 Nco I) in genetic susceptibility to migraine in North Indian population.
|
21668745 |
2011 |
|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The aim of the present observational study was to assess the value of the C825T polymorphism of the beta-3 subunit of G proteins (GNB3) as well as of variants in the SLC6A4 gene (5HTTLPR and STin2 VNTR) and DRD2 gene (TaqI A and NcoI) as predictive markers for consistency in headache response to triptans in migraine patients.
|
20488209 |
2010 |
|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These genetic differences could be explained by various genes, the HTR1B, encoding the 5-HT(1) receptor subtype, MAOA gene that encodes the monoamino-oxidase, the main metabolic enzyme of this triptan, SLC6A4 (gene encoding the serotonin transporter) and DRD(2) (gene encoding the D(2) receptor), both involved in the pathogenesis of migraine.
|
17563839 |
2007 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
There are various non-specific dopamine D(2) receptor antagonists that show good clinical efficacy in migraine, and also a number of polymorphisms of dopaminergic genes related to migraine.
|
17970991 |
2007 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The results of our study do not support a role for the DRD2 gene in modifying the clinical features of migraine.
|
15154861 |
2004 |
|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic studies on migraine suggested a role of CACNA1A and DRD2 genes as susceptibility genes in this disorder.
|
12811615 |
2003 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The DRD2 gene has also been implicated in schizophrenia, posttraumatic stress disorder, movement disorders and migraine.
|
12497624 |
2003 |
|
Migraine Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The -141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease.
|
11409701 |
2001 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, the dopamine D2 receptor (DRD2) was analyzed as a candidate gene since antagonists of this receptor have been reported to be effective in the acute treatment of migraine.
|
9222191 |
1997 |